BJH - volume 10, issue 7, november 2019
M. Vercruyssen , A. Van den Broeke , A. Salaroli , P. Nguyen , A. De Wind , N. Meuleman MD, PhD, D. Bron MD, PhD
Human T-cell leukaemia virus type 1 (HTLV-1) was the first human oncogenic virus discovered. It is endemic in some regions of the world but increasingly prevalent in our countries as globalisation is progressing. After several decades of asymptomatic carrying, approximately 2–5% of infected individuals will develop adult-T-cell leukaemia-lymphoma (ATL). Despite significant progress in the physiopathology and therapeutic interventions, the prognosis of this rare disease is dismal. An update of classification, clinical features, diagnosis and recent treatment recommendations is outlined in this review.
(BELG J HEMATOL 2019;10(7):277–84)
Read moreBJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
M. Vercruyssen , L. Vrancken , J. Caers MD, PhD
Multiple Myeloma (MM) and other plasma cell malignancies initially present as an asymptomatic precursor state, known as monoclonal gammopathy of undetermined significance (MGUS). When confronted to a monoclonal protein in blood or urine tests, physicians should first exclude the presence of a treatment-requiring MM. They should be aware that there are two benign precursor states, that do not require anti-myeloma treatment. Both MGUS and Smoldering Multiple Myeloma (SMM) need an initial visit by a haematologist, with further follow-up tailored to the individual patient and disease characteristics. In the current article we describe both entities, discuss their monitoring and resume the latest publications in their field.
Read moreBJH - volume 9, issue Multiple Myeloma Special Edition, december 2018
M. Vercruyssen , N. Meuleman MD, PhD
Patients with multiple myeloma (MM) not only require treatments directed at their disease activity, but also need a wide range of supportive measures. In this review article supportive measures with respect to anaemia, infections, thromboembolic risk, bone disease, peripheral neuropathy and pain are discussed.
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
C. Spilleboudt , F. Paciorkowski , M. Vercruyssen , L. Bienfait , M. Depierreux , M. Maerevoet MD, D. Bron MD, PhD, J. Nortier
BJH - 2018, issue Abstract Book BHS, february 2018
M. Vercruyssen , N. Cilla , L. Ameye , M. Paesmans , A. De Wind , P. Heimann MD, PhD, N. Meuleman MD, PhD, D. Bron MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
A. Pistone , M. Maerevoet MD, S. Wittnebel MD, PhD, M. Vercruyssen , S. Buntinx , C. Spilleboudt , D. Bron MD, PhD, N. Meuleman MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
D. Bron MD, PhD, A. Salaroli , N. Meuleman MD, PhD, M. Maerevoet MD, M. Vercruyssen , C. Spilleboudt , A. De Wind , G. Dapri , G.B. Cadiere , B. Cadiere
Top
